Literature DB >> 26633785

Neurosyphilis.

Christina M Marra.   

Abstract

PURPOSE OF REVIEW: This article reviews the etiology, clinical manifestations, diagnosis, and treatment of neurosyphilis, with a focus on issues of particular relevance to neurologists. RECENT
FINDINGS: The number of cases of infectious syphilis in the United States has steadily increased since 2000. The highest rates are among men who have sex with men, and approximately half of these individuals are infected with human immunodeficiency virus (HIV). Neurosyphilis is a serious complication of syphilis that can develop at any time in the course of syphilis. Two neuroimaging patterns should alert the neurologist to a diagnosis of neurosyphilis: cerebral gummas, which are dural-based lesions that can mimic meningiomas, and medial temporal lobe abnormalities that can mimic herpes encephalitis. Penicillin G is the recommended treatment for neurosyphilis, but ceftriaxone may be an acceptable alternative.
SUMMARY: The diagnosis of neurosyphilis can be challenging. A sound understanding of the clinical manifestations and the strengths and limitations of diagnostic tests are essential tools for the neurologist.

Entities:  

Mesh:

Year:  2015        PMID: 26633785     DOI: 10.1212/CON.0000000000000250

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  27 in total

1.  Meningovascular syphilis causing recurrent stroke and diagnostic difficulties: a scourge from the past.

Authors:  Sunil Munshi; Senthil K Raghunathan; Ileana Lindeman; Ashit K Shetty
Journal:  BMJ Case Rep       Date:  2018-06-08

2.  Concomitant neurosyphilis and herpes simplex encephalitis in an immunocompetent patient: a case report.

Authors:  Emmanuel Escobar-Valdivia; Isaí Medina-Piñón; Alexis García-Sarreon; Carlos R Camara-Lemarroy
Journal:  Neurol Sci       Date:  2017-09-15       Impact factor: 3.307

Review 3.  Neurosyphilis: Knowledge Gaps and Controversies.

Authors:  Susan Tuddenham; Khalil G Ghanem
Journal:  Sex Transm Dis       Date:  2018-03       Impact factor: 2.830

4.  Ceftriaxone - A plausible intervention for treating neurosyphilis?

Authors:  Syed Hasan Shuja; Unaiza Naeem; Farea Eqbal; Muhammad Hamza Shuja
Journal:  Ann Med Surg (Lond)       Date:  2022-09-15

5.  Brazilian Protocol for Sexually Transmitted Infections 2020: acquired syphilis.

Authors:  Francisca Lidiane Sampaio Freitas; Adele Schwartz Benzaken; Mauro Romero Leal de Passos; Ivo Castelo Branco Coelho; Angélica Espinosa Miranda
Journal:  Rev Soc Bras Med Trop       Date:  2021-05-17       Impact factor: 1.581

6.  Brazilian Protocol for Sexually Transmitted Infections 2020: syphilis diagnostic tests.

Authors:  Pâmela Cristina Gaspar; Álisson Bigolin; José Boullosa Alonso Neto; Esdras Daniel Dos Santos Pereira; Maria Luiza Bazzo
Journal:  Rev Soc Bras Med Trop       Date:  2021-05-17       Impact factor: 1.581

7.  Diagnostic tools for neurosyphilis: a systematic review.

Authors:  Gustavo Henrique Pereira Boog; João Vitor Ziroldo Lopes; João Vitor Mahler; Marina Solti; Lucas Tokio Kawahara; Andre Kakinoki Teng; João Victor Taba Munhoz; Anna S Levin
Journal:  BMC Infect Dis       Date:  2021-06-14       Impact factor: 3.090

8.  An Atypical Case of Neurosyphilis in a Patient With HIV: A Case Report.

Authors:  Elizabeth Chernyak; Hang Shi; Deborah A Theodore; Kiran T Thakur
Journal:  Neurohospitalist       Date:  2021-01-08

9.  Serological Response Predicts Normalization of Cerebrospinal Fluid Abnormalities at Six Months after Treatment in HIV-Negative Neurosyphilis Patients.

Authors:  Yao Xiao; Man-Li Tong; Li-Rong Lin; Li-Li Liu; Kun Gao; Mei-Jun Chen; Hui-Lin Zhang; Wei-Hong Zheng; Shu-Lian Li; Hui-Ling Lin; Zhi-Feng Lin; Tian-Ci Yang; Jian-Jun Niu
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

10.  The performance of rapid plasma reagin (RPR) titer in HIV-negative general paresis after neurosyphilis therapy.

Authors:  Ying Jiang; Ruihui Weng; Yuefeng Zhang; Rong Fan; Yulun Liu; Zhigang Chen; Fuhua Peng; Yong Chen; Xiaohong Chen
Journal:  BMC Infect Dis       Date:  2018-04-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.